-

Quantum Computing Market Trends and Investment Opportunities 2025-2035 Featuring Profiles of 115 Companies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Quantum Computing Market: Industry Trends and Global Forecasts - Distribution by Type of Drug Discovery Service Offered, Therapeutic Area and Key Geographical Regions" has been added to ResearchAndMarkets.com's offering.

The global quantum computing market is set for substantial growth, expanding from USD 422 million in the current year to an anticipated USD 1.63 billion by 2030, driven by a CAGR of 14.5% during the forecast period. One significant area of impact is drug discovery, traditionally an expensive and time-consuming process. The integration of quantum computing into the pharmaceutical sector revolutionizes this by efficiently identifying candidates with desired properties, circumventing extensive traditional screening processes.

Quantum computing operates on fundamentally different principles compared to conventional computing, utilizing quantum mechanics and enabling quantum superposition. This advancement has notably influenced the healthcare sector, improving interaction mapping and reducing development costs. Given these advantages, quantum computing is increasingly adopted in biopharmaceuticals, spawning lucrative opportunities for providers.

As per a recent report, key insights highlight the current market landscape. Over 45 global players offer quantum computing services in drug discovery, focusing on cancer-related therapies. Approximately 86% of stakeholders specialize in target identification. To stay competitive, companies are expanding their capabilities, with USD 70 million in grants advancing R&D efforts for quantum computing applications in drug discovery. Partnerships and collaborations have surged, with nearly 50% of alliances formed within the same region, focusing majorly on research and development agreements.

Globally, over 30 organizations provide quantum computing hardware-as-a-service, with many based in North America, established before 2000. This reflects significant contributions from large companies, which cover approximately 50% of the market. The increase in quantum computing adoption is poised to create expansive opportunities for both software and hardware providers, particularly with pioneering software companies leading long-term market offerings.

The market, predicted to grow at an annualized rate of 14.5%, shows potential well-distributed across service types, therapeutic areas, and key regions. Notably, lead optimization captures the largest market share, predicted to grow faster than other segments. CNS disorders represent the fastest-growing therapeutic area, while North America remains the dominant region, with Asia-Pacific poised for rapid growth.

Prominent players in this market include Accenture, Amazon Web Services, Atos, Fujitsu, Huawei, IBM, Microsoft, Xanadu, and XtalPi. The comprehensive report provides detailed insights into market sizing and opportunities, software and hardware provider landscapes, competitor analysis, profiles, grants, partnerships, and use cases. Notably, it includes a strategic guide for new players entering the market, utilizing Blue Ocean Strategy principles.

Reasons to acquire this report include gaining valuable insights on market dynamics, detailed revenue projections, competitive analysis, and market trends, aiding stakeholders in making informed decisions and optimizing strategies.

A selection of companies mentioned in this report includes, but is not limited to:

  • 1QBit
  • Accenture
  • Albert Einstein College of Medicine
  • Algorithmiq
  • Alibaba
  • Aliro Quantum
  • Allesh Biosciences Lab
  • Alzheimer's Research UK University College London Drug Discovery Institute
  • Amazon Web Services
  • Amgen
  • Anyon Systems
  • ApexQubit
  • Aqemia
  • Astex Pharmaceuticals
  • AstraZeneca
  • Atos
  • Auransa
  • Aurora Fine Chemicals
  • Automatski
  • Biogen
  • Bleximo
  • Boehringer Ingelheim
  • Brigham and Women's Hospital
  • C4X Discovery Holdings
  • Cambridge Quantum
  • ChemAlive
  • Cineca
  • Cisco
  • Cleveland Clinic
  • Cloud Pharmaceuticals
  • Conifer Point (Acquired by Lodo Therapeutics)
  • CreativeQuantum
  • Crown Biosciences International (Acquired by JSR Life Sciences)
  • Denovicon Therapeutics
  • D-wave
  • DXC Technology
  • Entropica Labs
  • Envisagenics
  • FAR Biotech
  • Fujitsu
  • Good Chemistry
  • Google
  • GTN
  • Hafnium Labs
  • Hewlett Packard Enterprise (HPE)
  • Hypertrust Patient Data Care (HPDC)
  • Honeywell
  • Hybrid Quantum Architectures and Networks
  • IBM
  • Iktos
  • Indian Institute of Technology, Madras
  • Infosys
  • IonQ
  • IQM
  • Janssen Pharmaceuticals
  • Kuano
  • Kynogen
  • Menten AI
  • Ministry of Electronics and Information Technology
  • Molecular Quantum Solutions
  • Multiverse
  • National Heart, Lungs and Blood Institute (NHLBI)
  • National Institute of Health
  • Netramark (Acquired by Nurosene Health)
  • NVIDIA
  • Osaka University
  • OVHcloud
  • Oxford Quantum Circuits (OQC)
  • Pacific Northwest National Laboratory (PNNL)
  • PASQAL
  • Pfizer
  • Pharmacelera
  • PharmCADD
  • PhoreMost
  • PiDust
  • Polaris Quantum Biotech
  • Profacgen
  • ProteinQure
  • QC Ware
  • QpiAI
  • QRDLab
  • QSimulate
  • Qu&Co
  • Quantinuum
  • Quantum Brilliance
  • Qubit Pharmaceuticals
  • Quantronics Laboratory (QuLab)
  • Qunova Computing
  • Rescale
  • Rigetti Computing
  • RIKEN
  • Riverlane
  • Roche
  • Roivant Discovery
  • Sanofi
  • SAP
  • SEEQC
  • Servier
  • Siemens
  • SpinQ StationQ (Subsidiary of Microsoft)
  • Tata Consultancy Services
  • Terra Quantum
  • Texas A&M AgriLife Research
  • Toshiba
  • UCL Quantum Science and Technology Institute
  • University of Bristol Quantum Information Institute
  • University of California
  • University of Chicago
  • University of Illinois
  • University of North Carolina System (UNC)
  • University of Notre Dame
  • University of Ottawa
  • Xanadu
  • XtalPi
  • Zapata Computing

For more information about this report visit https://www.researchandmarkets.com/r/hwrhqr

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Understanding Medical Device Regulatory Pathways - 510(k), PMA & Exemptions Webinar - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Understanding Medical Device Regulatory Pathways - 510(k), PMA & Exemptions (January 15, 2026)" training has been added to ResearchAndMarkets.com's offering. This expert-led 3-hour webinar provides a comprehensive introduction to the key regulatory pathways for medical device submissions in the US market. The regulation and control of new or substantially changed medical devices for sale in the US is based on the 510(k), PMA or DeNovo submission process. This w...

Medical Devices: Section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) Course: Developing Effective Post Market Surveillance and Complaint Handling Systems Training - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Medical Devices: Developing Effective Post Market Surveillance and Complaint Handling Systems Course (Jan 22nd - Jan 23rd, 2026)" training has been added to ResearchAndMarkets.com's offering. What are U.S. FDA CGMP expectations/requirements for Post Market Surveillance and Complaint Handling? This seminar will examine Section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as well as appropriate articles / Annexes of the EU's MDR, which require manu...

Statistical Process Control (SPC) Training: An Exercise-Based Course - Key Methodology Used in Quality Management to Monitor, Control, and Improve Process Performance (February 6, 2026 & On-Demand) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Statistical Process Control (SPC): An Exercise-Based Training Course (February 6, 2026)" training has been added to ResearchAndMarkets.com's offering. This course provides an in-depth understanding of Statistical Process Control (SPC), a key methodology used in quality management to monitor, control, and improve process performance. This 6-hour virtual seminar includes a presentation of the steps and techniques used to quantify variability in manufacturing processe...
Back to Newsroom